Clene Nanomedicine's CNM-Au8 is currently in an open-label extension phase following a Phase 2 randomized, double-blind, placebo-controlled trial for early symptomatic Amyotrophic Lateral Sclerosis (ALS). The market for ALS therapies is expanding, with a growing demand for innovative treatments that can slow disease progression. The successful completion of this trial could position Clene favorably against competitors in the neurodegenerative space, particularly as there are limited effective therapies for ALS. The open-label extension allows for continued patient engagement and data collection, potentially enhancing the drug's profile and supporting future regulatory submissions.